Amgen adds $300M investment to biologics manufacturing facility in Puerto Rico

California-headquartered biotechnology company Amgen is investing an additional $300 million to expand its biologics manufacturing facility in Juncos, Puerto Rico. The latest outlay for the site is meant to advance the biotech’s U.S.-based production capacity and enhance next-generation technologies, according to the announcement.

Amgen contends that its Juncos site is already one of the world’s “largest and most advanced” biomanufacturing facilities, producing biologic medicines for more than 60 countries around the globe. In September 2025, the company announced that it was investing $650 million to expand the Puerto Rican biologics facility to increase drug production capacity and integrate advanced technologies across operations.

The latest investment reflects Amgen’s commitment to strengthening U.S. biomanufacturing and global supply chain resilience, according to the company.

“By growing our operations in Puerto Rico, we are ensuring patients have access to the medicines they need, investing in the long-term strength of our domestic supply chain and supporting American jobs,” Amgen CEO Robert Bradway said in a statement.

Amgen noted in its announcement that the Puerto Rico expansion builds on more than $40 billion invested in U.S. manufacturing and R&D since the enactment of the Tax Cuts and Jobs Act (TCJA) of 2017.

“Pro-growth tax policies in TCJA, extended and reinforced by the One Big Beautiful Bill Act of 2025, support the company’s ability to invest in domestic science and manufacturing,” according to Amgen.

In addition to a nearly $1 billion investment in the Puerto Rico facility, the company has announced planned investments of $900 million in Ohio and $600 million in a science and innovation center in California. Amgen has also recently invested more than $1.5 billion in North Carolina. 

Puerto Rico’s importance grows

Biopharmaceutical companies like Amgen continue to invest in their manufacturing infrastructure in Puerto Rico, advancing the island’s role as a biopharma hub. Governor Jenniffer González Colón noted in Amgen’s announcement about its $300 million investment that Puerto Rico has “more than 60 years of excellence” in the biopharma sector, supported by a highly skilled workforce and world‑class infrastructure.

In October 2025, Eli Lilly announced an investment of more than $1.2 billion to expand and modernize its site in Carolina, Puerto Rico, supporting the drugmaker’s growing portfolio of oral solid medicines in cardiometabolic health, neuroscience, oncology, and immunology.

The expansion at the Lilly del Caribe site is meant to boost its U.S. oral medicine production capacity and integrate advanced technologies, including dock-to-dock automation and material flow, paperless manufacturing, process analytical technology, as well as spray-dried dispersion — which allows oral medicines to be effectively absorbed.

Last month, Taiwan-headquartered biopharma company PharmaEssentia signed an investment agreement for a new manufacturing facility in Toa Baja, Puerto Rico to establish a dual-site production network.

The facility is designed to the same standards as PharmaEssentia’s existing manufacturing site in Taichung, Taiwan, with personnel from the Puerto Rico facility expected to complete training in Taiwan to support knowledge transfer and operational readiness.